| Source: HalifaxProj(inhibit) |
| Type: |
| NF-kB signaling Nuclear factor kappa B (NF-κB) is a transcription factor that plays a crucial role in regulating immune response, inflammation, cell proliferation, and survival. NF-κB is often found to be constitutively active in many types of cancer cells. This persistent activation can promote tumorigenesis by enhancing cell survival, proliferation, and metastasis. |
| 2639- | Api, | Plant flavone apigenin: An emerging anticancer agent |
| - | Review, | Var, | NA |
| 2319- | Api, | Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis |
| - | in-vitro, | GBM, | NA |
| 2318- | Api, | Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems |
| - | Review, | Nor, | NA |
| 1095- | Api, | Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway |
| - | Analysis, | Colon, | NA |
| 581- | Api, | Cisplatin, | The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy |
| - | in-vitro, | Pca, | CD44+ |
| 589- | Api, | 5-FU, | Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro |
| - | in-vitro, | PC, | Bxpc-3 |
| 211- | Api, | Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice |
| - | in-vivo, | Pca, | NA |
| 171- | Api, | Apigenin in cancer therapy: anti-cancer effects and mechanisms of action |
| - | Review, | Var, | NA |
| 240- | Api, | The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | CD44+ |
| 237- | Api, | Apigenin blocks IKKα activation and suppresses prostate cancer progression |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | 22Rv1 | - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | DU145 |
| 416- | Api, | In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma |
| - | vitro+vivo, | NA, | NA |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3385- | ART/DHA, | Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study |
| - | Study, | NA, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 3392- | ART/DHA, | Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways |
| - | in-vitro, | Nor, | Hep3B | - | in-vivo, | NA, | NA |
| 3665- | ART/DHA, | Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation |
| - | Review, | AD, | NA |
| 3666- | ART/DHA, | Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling |
| - | NA, | AD, | NA |
| 3667- | ART/DHA, | Artemisinin improves neurocognitive deficits associated with sepsis by activating the AMPK axis in microglia |
| - | Review, | Sepsis, | NA |
| 5136- | ART/DHA, | Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis |
| - | in-vitro, | Var, | NA |
| 5134- | ART/DHA, | Dihydroartemisinin induces autophagy by suppressing NF-κB activation |
| - | in-vitro, | Var, | NA |
| 556- | ART/DHA, | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
| - | Review, | NA, | NA |
| 558- | ART/DHA, | Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer |
| - | Review, | NA, | NA |
| 2324- | ART/DHA, | Research Progress of Warburg Effect in Hepatocellular Carcinoma |
| - | Review, | Var, | NA |
| 5793- | ASA, | Aspirin Recapitulates Features of Caloric Restriction |
| - | in-vitro, | Nor, | NA |
| 1142- | Ash, | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
| - | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
| 5396- | Ash, | Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology |
| - | Review, | Var, | NA |
| 3685- | Ash, | Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation |
| - | in-vivo, | NA, | NA |
| 3687- | Ash, | Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives |
| - | Review, | AD, | NA |
| 3689- | Ash, | Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells |
| - | in-vitro, | NA, | NRK52E |
| 3174- | Ash, | Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3155- | Ash, | Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera |
| - | Review, | Var, | NA |
| 3156- | Ash, | Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug |
| - | Review, | Var, | NA |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 3166- | Ash, | Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives |
| - | Review, | Var, | NA |
| 3162- | Ash, | Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A |
| - | Review, | Var, | NA |
| 1362- | Ash, | GEM, | Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Hs766t |
| 1181- | Ash, | Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 1177- | Ash, | Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis |
| - | in-vivo, | EC, | NA |
| 5170- | Ash, | Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ |
| - | Review, | Var, | NA |
| 5174- | Ash, | Withaferin A is a potent inhibitor of angiogenesis |
| - | in-vitro, | Nor, | HUVECs |
| 4820- | ASTX, | Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p |
| - | in-vitro, | NPC, | NA |
| 4810- | ASTX, | Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 5419- | ASTX, | Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications |
| - | Review, | Nor, | NA |
| 5425- | ASTX, | Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights |
| - | in-vivo, | AD, | NA |
| 147- | ATG, | EGCG, | CUR, | Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | MCF-7 |
| 5365- | AV, | Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
| 5568- | B-Gluc, | immuno, | Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting |
| - | Review, | Var, | NA |
| 5577- | B-Gluc, | Lentinan progress in inflammatory diseases and tumor diseases |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 874- | B-Gluc, | Potential promising anticancer applications of β-glucans: a review |
| - | Review, | NA, | NA |
| - | in-vivo, | BC, | 4T1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:214 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid